Peptides by condition · Weight, blood sugar, liver and gut
Peptides studied for celiac disease
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 3 study pages on celiac disease: 3 in people (all meta-analyses or randomized trials). They studied one compound, Larazotide.
What the research on celiac disease looks like
Celiac disease is an immune disease in which gluten, a protein in wheat, barley and rye, sets off an attack on the lining of the small intestine. The one accepted way to live with it is a strict gluten-free diet for life, yet many people still have symptoms on that diet, often from traces of gluten they did not know they ate. The peptide studied here, larazotide, is a small peptide taken by mouth before meals. It is meant to tighten the seals between the cells of the gut lining, so that less gluten slips through them.
These trials score gut symptoms such as belly pain, bloating and diarrhea on questionnaires written for celiac disease, and count the days with symptoms. Some also measure how leaky the gut lining is with a sugar test: people drink two sugars, lactulose and mannitol, and the ratio that comes out in the urine shows how much slipped through. Several trials fed people a measured amount of gluten, called a gluten challenge, to see what the drug did against it.
Look at whether a trial gave people gluten on purpose or followed them on their usual gluten-free diet, because the results differed between the two. Check which dose did what: in one large trial the lowest dose did better than the higher ones, a pattern that needs another trial before anyone leans on it. Symptom scores respond to placebo, and the sugar test measures the gut lining, not the damage a biopsy of the intestine shows.

The 3 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Larazotide
3 in peopleFor celiac disease, 3 of our study pages are filed under Larazotide: 1 meta-analysis and 2 randomized trials in people. The largest in people pooled 626 people and was published in 2022. They were published from 2007 to 2022, in Clin Res Hepatol Gastroenterol, Gastroenterology and Aliment Pharmacol Ther.
Larazotide has no FDA-approved product: Drugs@FDA lists no application for it.
- Meta-analysis in people · 626 people · 2022Larazotide: eased GI symptoms in celiac patients on gluten challenge
- Randomized trial in people · 342 people · 2015Larazotide: 0.5 mg arm eased celiac symptoms on gluten-free diet
- Randomized trial in people · 2007Larazotide: no gut permeability rise after gluten in celiac patients
Side by side
For the compound on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Larazotide | 3 | 0 | 626 | Not approved |
- In people
- 3
- Animals or cells
- 0
- Largest in people
- 626
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Larazotide: eased GI symptoms in celiac patients on gluten challengeThe pooled evidence comes from a small number of trials, with even fewer in patients on a gluten-free diet. The authors say more randomized trials are needed to confirm the results.
- Larazotide: 0.5 mg arm eased celiac symptoms on gluten-free dietThis was a 12-week phase II trial, and only the lowest dose beat placebo while the higher doses did not, so the results were mixed. Most of the extra benefits came from exploratory measures, not the main goal.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for celiac disease?
Our 3 study pages on celiac disease are all filed under one compound, Larazotide.
Have any been tested in people with celiac disease?
Yes: all 3 were in people, all of them meta-analyses or randomized trials (Larazotide). The largest pooled 626 people: “Larazotide: eased GI symptoms in celiac patients on gluten challenge” (2022).
Is any peptide FDA-approved for celiac disease?
Not by the labels our status pages read: of the one compound here with an FDA record, none has a use tied to celiac disease.
How large were the studies in people on celiac disease?
Of the 3 in people, 2 give their size on our pages: 2 had 100 to 999. The largest, a meta-analysis from 2022, pooled 626.
What is the newest study on celiac disease here?
Of our study pages on celiac disease, the newest is “Larazotide: eased GI symptoms in celiac patients on gluten challenge”, a meta-analysis in people published in 2022.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.